SCHEMBL837816

SCHEMBL837816

O=C1Cc2c(NCC(=O)OCc3ccccc3)cccc2N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.45
DRD4 P21917 2/20 0.45
DRD3 P35462 2/20 0.45
MAPK1 P28482 2/20 0.45
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DHPS P49366 1/20 0.43
BRD4 O60885 1/20 0.42
CREBBP Q92793 1/20 0.42
CASP3 P42574 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PLAU P00749 2/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837797 0.81 DHPS (0.51) DRD2DRD4DRD3MAPK1DHPS
SCHEMBL27691781 0.78 DRD2 (0.44) DRD2DRD4DRD3MAPK1NPC1
SCHEMBL28598894 0.76 ALDH1A1 (0.53) MAPK1NPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL7443236 0.73 DRD2 (0.63) DRD2DRD4DRD3SMN1; SMN2DHPS
SCHEMBL20697269 0.73 ALDH1A1 (0.46) MAPK1NPC1GAARAB9ACASP3
SCHEMBL8688821 0.72 ALDH1A1 (0.51) MAPK1NPC1GAARAB9ASMN1; SMN2
SCHEMBL5638400 0.71 DRD2 (0.67) DRD2DRD4DRD3MAPK1BRD4
SCHEMBL7448312 0.70 DRD2 (0.45) DRD2DRD4DRD3MAPK1SMN1; SMN2
SCHEMBL8053191 0.70 SIRT2 (0.53) MAPK1NPC1RAB9AL3MBTL1ALDH1A1
SCHEMBL2014359 0.70 ALDH1A1 (0.53) MAPK1NPC1RAB9AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143266-B2 Aryl heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp (US) 2012-03-27 US disclosed
EP-1794133-B1 ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-12-14 EP disclosed
US-7989624-B2 Aryl spirolactam CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-08-02 US disclosed
US-20100120809-A1 ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-05-13 US disclosed
EP-2146712-A1 ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2010-01-27 EP disclosed
WO-2008130524-A1 ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-10-30 WO disclosed
US-20080004304-A1 Aryl Spirolactam Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-01-03 US disclosed
EP-1794133-A2 ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-06-13 EP disclosed
WO-2006031513-A2 ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120809-A1 ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS BDKRB1, BDKRB2, CCKBR DRD2 745/4885DRD4 1379/4885DRD3 697/4885
US-20080004304-A1 Aryl Spirolactam Cgrp Receptor Antagonists BDKRB1, BDKRB2, CALCRL DRD2 866/4885DRD4 1451/4885DRD3 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.